The yield on the benchmark 10-year Treasury note fell to its lowest level since September 2017 as the Fed began its two-day policy meeting.Bondsread more
The move is part of a larger trend that saw the survey's 179 participants move away from risk and toward positions that reflect fear of a coming economic slowdown spurred by a...Marketsread more
Shares of Beyond Meat soared 18% in premarket trading Tuesday, surpassing $200 per share.Food & Beverageread more
Investors bracing themselves for lower Federal Reserve rates should think about loading up on health care stocks, history shows.Marketsread more
Trump went after Draghi for opening the door for more monetary stimulus in Europe, which would weaken the euro relative to the dollar.Marketsread more
Private equity billionaire David Rubenstein says he's spoken with U.S. and Chinese officials. "My view is both sides want a deal."Economyread more
The yoga-pants retailer is now selling such personal-care products as face moisturizer, dry shampoo, deodorant and lip balm.Retailread more
Hershey CEO Michele Buck said that the 125-year-old company is monitoring the trend but doesn't have any plans to add CBD to its food just yet.Food & Beverageread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
Restaurants have a hard time hiring and retaining dishwashers, but now there's a robot for that.At Workread more
Experts expect Facebook's cryptocurrency venture to alleviate some security issues, while introducing new ones.Technologyread more
Merck on Wednesday said the U.S. Food and Drug Administration intends to rescind its "breakthrough therapy" designation for its experimental combination treatment for hepatitis C because of other recently approved treatments.
Merck, in its fourth-quarter earnings report, said it plans to discuss the matter with the FDA, and still expects to seek U.S. approval for the treatment in the first half of 2015. It consists of a protease inhibitor called MK-5172 and a so-called NS5A inhibitor called MK-8742 that together had received the "breakthrough therapy" designation from the FDA.
Merck in June announced it would ramp up its involvement in the lucrative hepatitis C market by buying Idenix Pharmaceuticals for $3.85 billion and combining the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C. It agreed to pay $24.50 per share, more than three times Idenix's price before the deal was made public.
Idenix had three drugs in development to treat hepatitis C, most notably a pill in early-stage trials called IDX21437. Like Gilead's new drug Sovaldi, it is a nucleotide inhibitor—or "nuc"—that blocks a protein needed by the hepatitis C virus to replicate.
Merck has hoped to eventually combine IDX21437 with MK-5172 and MK-8742.
Merck reported slightly disappointing quarterly sales and predicted 2015 earnings below analyst forecasts, citing the negative impact of the stronger dollar, as most of its U.S. rivals have done in making their own cautious forecasts.
Merck said it expects full-year 2015 earnings of $3.32 to $3.47 per share, excluding special items, with foreign exchange factors crimping earnings by 27 cents per share. Wall Street had predicted $3.49 per share.
The second-biggest U.S. drugmaker on Wednesday said it earned $7.32 billion, or $2.54 per share, in the fourth quarter. That compared with $781 million, or 26 cents per share, in the year-earlier period.
Excluding special items, the company earned 87 cents per share. Analysts, on average, expected 85 cents per share, according to Thomson Reuters I/B/E/S.
Company revenue fell 7 percent to $10.48 billion, trailing Wall Street expectations of $10.5 billion, held back by lower sales of its Remicade arthritis drug, now facing competition abroad from cheaper generics.
Sales would have fallen 4 percent if not for the stronger dollar, which lowers the value of sales abroad, when converted back into U.S. currency.